SuperworthAytu Biopharma AYTU
- Market cap
- $20.6M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.4×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $57.6M
- −13% on a year ago
- Net margin
- −24.8%
- Free cash flow yield
- 15.8%
Aytu Biopharma trades at 0.4× sales. Revenue was $57.6M over the last twelve months, down 13% on a year earlier with a −25% net margin.
Charts
Financials
| Income statement | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $17.8M−36% | $18.7M−29% | $14M−38% | $14.6M−53% | $16.6M−7% | $16.2M−14% | $18.5M+32% | $15.1M+4% | $13.9M−16% | $15.2M−7% | $12.4M−33% | $16.1M+6% | |
| Cost of revenue | $4.8M−50% | $4.1M−54% | $3.7M−63% | $3.5M−71% | $4.6M−4% | $5.4M+31% | $5.6M+54% | $4.9M+38% | $4.7M+3% | $5.5M+2% | $4.8M−15% | $5.7M+17% |
| Gross profit | $13M−28% | $14.6M−16% | $10.4M−19% | $11.1M−41% | $12M−8% | $10.8M−26% | $12.8M+24% | $10.3M−7% | $9.2M−23% | $9.6M−11% | $7.6M−41% | $10.4M+2% |
| R&D | $595K−44% | $521K−70% | $611K−29% | $1M+124% | $426K−28% | $522K+0% | $162K−74% | $216K−79% | $0 | $0 | $0 | $0 |
| SG&A | $12.4M−29% | $10M−46% | $10.2M−49% | $9.4M−33% | $10.8M−13% | $9.7M−3% | $9.3M−9% | $8.5M−10% | $10.2M−5% | $11.1M+14% | $10.9M+17% | $10.4M+23% |
| −$867K−52% | $3.1M | −$1.6M−81% | −$2.3M | −$930K+7% | −$1.7M | $2.4M | −$7.6M+235% | −$1.5M+62% | −$2M+16% | −$4.1M | −$777K−90% | |
| Interest expense | $1.3M+114% | $1.3M+81% | $1.3M+80% | $1.3M−58% | $994K−23% | $1.1M−15% | $900K−28% | $730K−42% | $516K−48% | $560K−48% | $436K−52% | $383K−48% |
| Pre-tax income | −$7.5M+966% | $1.4M | −$1.8M−76% | −$2.5M+3% | $1.5M | $382K−73% | $3.8M | −$19.4M+666% | $2M+31% | −$10.6M | −$5.6M | −$4K−100% |
| $0 | $780K | $521K | $841K | $405K | −$283K | −$122K | $437K−48% | $0 | $0 | $10K | $11K−98% | |
| Net income | −$8.1M+1058% | −$220K−97% | −$2.9M−60% | −$4.6M+88% | $1.5M | $788K | $4M | −$19.8M+329% | $2M+33% | −$10.6M | −$5.6M | −$15K−100% |
| −$1.48+429% | −$0.04−98% | −$0.52−73% | n/a | −$0.15−90% | −$0.26+550% | $0.21 | n/a | −$0.08−47% | −$1.05+304% | −$0.53 | n/a | |
| 5.5M+118% | 5.5M+77% | 5.5M+49% | n/a | 9.1M+66% | 8.5M+54% | 8.2M+48% | n/a | 19.5M+114% | 10M+18% | 10.5M+28% | n/a |
Gross profit: 23 periods, Q1 FY15 to Q4 FY20: not printed by the filing, worked out from its own lines.
Operating income: Q3 FY14 and Q3 FY15: not printed by the filing, worked out from its own lines.
EPS, diluted: 9 periods, Q4 FY15 to Q4 FY23: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY15: a loss quarter: its basic count, share-days: the 12-month average over 365 days less the 9-month over 274, the two on one basis (x12). Q4 FY16: a loss quarter: its basic count, share-days: the 12-month average over 366 days less the 9-month over 275, the two on one basis (x20). 6 periods, Q4 FY17 to Q4 FY23: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY18: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Aytu Biopharma's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| AYTUAytu Biopharma | $20.6M | n/m | n/a | 0.4× | −13% | −24.8% | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| Peer median | $64.6M | 10.1× | 9.5× | 0.9× | −12% | 9.2% |
More on Aytu Biopharma
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #10of 199Healthcare stocks with the highest free cash flow yield
- #8of 157Large drugmakers with the lowest price to sales ratio
- #4of 44Large drugmakers with the highest free cash flow yield
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .